{
    "Collaborators": [
        {
            "CollaboratorName": "Ottawa Heart Institute Research Corporation",
            "CollaboratorClass": "OTHER"
        }
    ],
    "PrimaryOutcomes": [
        {
            "PrimaryOutcomeMeasure": "Numeric Pain Rating Scale",
            "PrimaryOutcomeDescription": "Perceived pain. Self-perceived pain intensity will be evaluated by a 0 to 10 Numeric Pain Rating Scale (NPRS), where 0 denotes no pain and 10 denotes the maximum possible pain.",
            "PrimaryOutcomeTimeFrame": "pre-treatment, 1 week, 4 week, 12 week."
        }
    ],
    "SecondaryOutcomes": [
        {
            "SecondaryOutcomeMeasure": "Algometry",
            "SecondaryOutcomeDescription": "Pain threshold to pressure at specific tender points of the shoulder: infraspinatus, deltoid and trapezius. PPT levels defined as the minimum pressure required to evoke pain will be assessed using a portable electronic pressure algometer. Change from baseline on algometry. The units of measurement of pressure pain will be Kg/cm2.",
            "SecondaryOutcomeTimeFrame": "pre-treatment, 1 week, 4 week, 12 week."
        }
    ],
    "OverallOfficials": [
        {
            "OverallOfficialName": "Douglas K trask, MD. Ph.D.",
            "OverallOfficialAffiliation": "University of Iowa",
            "OverallOfficialRole": "PRINCIPAL_INVESTIGATOR"
        }
    ],
    "Locations": [
        {
            "LocationFacility": "University of Iowa Department of Otolaryngology",
            "LocationCity": "Iowa City",
            "LocationState": "Iowa",
            "LocationZip": "52242",
            "LocationCountry": "United States"
        }
    ],
    "ArmGroups": [
        {
            "ArmGroupLabel": "USUAL PHYSIOTHERAPY",
            "ArmGroupType": "ACTIVE_COMPARATOR",
            "ArmGroupDescription": "the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.",
            "ArmGroupInterventionName": "Procedure: common Physical therapy"
        }
    ],
    "Interventions": [
        {
            "InterventionType": "DRUG",
            "InterventionName": "Esomeprazole (Nexium)"
        }
    ],
    "StudyReferences": [
        {
            "ReferencePMID": "16845694",
            "ReferenceType": "BACKGROUND",
            "ReferenceCitation": "Hartel M, Hoffmann G, Wente MN, Martignoni ME, Buchler MW, Friess H. Randomized clinical trial of the influence of local water-filtered infrared A irradiation on wound healing after abdominal surgery. Br J Surg. 2006 Aug;93(8):952-60. doi: 10.1002/bjs.5429."
        }
    ],
    "ConditionMeshes": [
        {
            "ConditionMeshId": "D000006258",
            "ConditionMeshTerm": "Head and Neck Neoplasms"
        }
    ],
    "ConditionAncestors": [
        {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
        }
    ],
    "ConditionBrowseLeaves": [
        {
            "ConditionBrowseLeafId": "M9348",
            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
            "ConditionBrowseLeafAsFound": "Head and Neck Cancer",
            "ConditionBrowseLeafRelevance": "HIGH"
        }
    ],
    "ConditionBrowseBranches": [
        {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
        }
    ],
    "InterventionMeshes": [
        {
            "InterventionMeshId": "D000064098",
            "InterventionMeshTerm": "Esomeprazole"
        }
    ],
    "InterventionAncestors": [
        {
            "InterventionAncestorId": "D000000897",
            "InterventionAncestorTerm": "Anti-Ulcer Agents"
        }
    ],
    "InterventionBrowseLeaves": [
        {
            "InterventionBrowseLeafId": "M30204",
            "InterventionBrowseLeafName": "Esomeprazole",
            "InterventionBrowseLeafAsFound": "In the morning",
            "InterventionBrowseLeafRelevance": "HIGH"
        }
    ],
    "InterventionBrowseBranches": [
        {
            "InterventionBrowseBranchAbbrev": "Gast",
            "InterventionBrowseBranchName": "Gastrointestinal Agents"
        }
    ],
    "protocolSection.outcomesModule.otherOutcomes": [
        {
            "OtherOutcomeMeasure": "Change in Prenatal Distress at 12-weeks post-randomization",
            "OtherOutcomeDescription": "The Prenatal Distress Scale (range: 0-35) is an 18-item scale that assesses the things that are worrisome or bothersome about their pregnancy in which a higher score indicates a worse outcome.",
            "OtherOutcomeTimeFrame": "12-weeks post-randomization"
        }
    ],
    "protocolSection.contactsLocationsModule.centralContacts": [
        {
            "CentralContactName": "Adolfo Rosado Portillo",
            "CentralContactRole": "CONTACT",
            "CentralContactPhone": "605663879",
            "CentralContactEMail": "adolforosadoportillo@gmail.com"
        }
    ],
    "resultsSection.participantFlowModule.groups": [
        {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Blinded Active Vaccine 2",
            "FlowGroupDescription": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly followed by a wash out period of 24 hours then crossover to receive placebo (0.3 mL normal saline) intramuscularly."
        }
    ],
    "resultsSection.participantFlowModule.periods": [
        {
            "FlowPeriodTitle": "First Period of Crossover",
            "resultsSection.participantFlowModule.periods.milestones": [
                {
                    "FlowMilestoneType": "STARTED",
                    "resultsSection.participantFlowModule.periods.milestones.achievements": [
                        {
                            "FlowAchievementGroupId": "FG000",
                            "FlowAchievementNumSubjects": "8"
                        }
                    ]
                }
            ]
        }
    ],
    "resultsSection.baselineCharacteristicsModule.groups": [
        {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Blinded Active Vaccine 2",
            "BaselineGroupDescription": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly followed by a wash out period of 24 hours then crossover to receive placebo (0.3 mL normal saline) intramuscularly."
        }
    ],
    "resultsSection.baselineCharacteristicsModule.denoms": [
        {
            "BaselineDenomUnits": "Participants",
            "resultsSection.baselineCharacteristicsModule.denoms.counts": [
                {
                    "BaselineDenomCountGroupId": "BG000",
                    "BaselineDenomCountValue": "8"
                },
                {
                    "BaselineDenomCountGroupId": "BG001",
                    "BaselineDenomCountValue": "8"
                },
                {
                    "BaselineDenomCountGroupId": "BG002",
                    "BaselineDenomCountValue": "16"
                }
            ]
        }
    ],
    "resultsSection.baselineCharacteristicsModule.measures": [
        {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "COUNT_OF_PARTICIPANTS",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "resultsSection.baselineCharacteristicsModule.measures.classes": [
                {
                    "resultsSection.baselineCharacteristicsModule.measures.classes.categories": [
                        {
                            "BaselineCategoryTitle": "<=18 years",
                            "resultsSection.baselineCharacteristicsModule.measures.classes.categories.measurements": [
                                {
                                    "BaselineMeasurementGroupId": "BG000",
                                    "BaselineMeasurementValue": "0"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG001",
                                    "BaselineMeasurementValue": "0"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG002",
                                    "BaselineMeasurementValue": "0"
                                }
                            ]
                        },
                        {
                            "BaselineCategoryTitle": "Between 18 and 65 years",
                            "resultsSection.baselineCharacteristicsModule.measures.classes.categories.measurements": [
                                {
                                    "BaselineMeasurementGroupId": "BG000",
                                    "BaselineMeasurementValue": "8"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG001",
                                    "BaselineMeasurementValue": "7"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG002",
                                    "BaselineMeasurementValue": "15"
                                }
                            ]
                        },
                        {
                            "BaselineCategoryTitle": ">=65 years",
                            "resultsSection.baselineCharacteristicsModule.measures.classes.categories.measurements": [
                                {
                                    "BaselineMeasurementGroupId": "BG000",
                                    "BaselineMeasurementValue": "0"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG001",
                                    "BaselineMeasurementValue": "1"
                                },
                                {
                                    "BaselineMeasurementGroupId": "BG002",
                                    "BaselineMeasurementValue": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "resultsSection.outcomeMeasuresModule.outcomeMeasures": [
        {
            "OutcomeMeasureType": "PRIMARY",
            "OutcomeMeasureTitle": "Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine",
            "OutcomeMeasureDescription": "Proportion of participants who had recurrent systemic allergic reaction following active COVID-19 vaccine dose in this study. Allergic reactions were graded using Consortium of Food Allergy Research (CoFAR) grading scale (Version 3.0) where Grade 1 (mild) = mild symptoms involving one organ system (skin, conjunctiva, upper respiratory or gastrointestinal); Grade 2 (moderate) = mild symptoms involving \u22652 organ system (skin, conjunctiva, upper respiratory or gastrointestinal); Grade 3 (severe)= moderate to severe cardiovascular, lower respiratory or gastrointestinal symptoms, responsive to treatment and/or without end-organ dysfunction; Grade 4 = severe cardiovascular or lower respiratory symptoms, with end-organ dysfunction and/or refractory to treatment; and Grade 5 = death.\n\nSystemic allergic reaction was defined as CoFAR grade 1 reaction with elevated tryptase or CoFAR Grade \u2265 2 reaction irrespective of tryptase levels.",
            "OutcomeMeasurePopulationDescription": "The analysis included participants who received the active study vaccine in the crossover phase as pre-specified in the protocol to only collect and report data from the active vaccination.",
            "OutcomeMeasureReportingStatus": "POSTED",
            "OutcomeMeasureParamType": "NUMBER",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "Proportion of participants",
            "OutcomeMeasureTimeFrame": "Within the 3-hour post-vaccine observation period",
            "resultsSection.outcomeMeasuresModule.outcomeMeasures.groups": [
                {
                    "OutcomeGroupId": "OG000",
                    "OutcomeGroupTitle": "Blinded Active Vaccine 2",
                    "OutcomeGroupDescription": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly"
                }
            ],
            "resultsSection.outcomeMeasuresModule.outcomeMeasures.denoms": [
                {
                    "OutcomeDenomUnits": "Participants",
                    "resultsSection.outcomeMeasuresModule.outcomeMeasures.denoms.counts": [
                        {
                            "OutcomeDenomCountGroupId": "OG000",
                            "OutcomeDenomCountValue": "16"
                        }
                    ]
                }
            ],
            "resultsSection.outcomeMeasuresModule.outcomeMeasures.classes": [
                {
                    "resultsSection.outcomeMeasuresModule.outcomeMeasures.classes.categories": [
                        {
                            "resultsSection.outcomeMeasuresModule.outcomeMeasures.classes.categories.measurements": [
                                {
                                    "OutcomeMeasurementGroupId": "OG000",
                                    "OutcomeMeasurementValue": "0.125",
                                    "OutcomeMeasurementLowerLimit": "0.016",
                                    "OutcomeMeasurementUpperLimit": "0.383"
                                }
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "resultsSection.adverseEventsModule.eventGroups": [
        {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Blinded Active Vaccine 2",
            "EventGroupDescription": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly",
            "EventGroupDeathsNumAffected": 0,
            "EventGroupDeathsNumAtRisk": 16,
            "EventGroupSeriousNumAffected": 0,
            "EventGroupSeriousNumAtRisk": 16,
            "EventGroupOtherNumAffected": 3,
            "EventGroupOtherNumAtRisk": 16
        }
    ],
    "resultsSection.adverseEventsModule.otherEvents": [
        {
            "OtherEventTerm": "Anaemia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventAssessmentType": "SYSTEMATIC_ASSESSMENT",
            "resultsSection.adverseEventsModule.otherEvents.stats": [
                {
                    "OtherEventStatsGroupId": "EG000",
                    "OtherEventStatsNumAffected": 0,
                    "OtherEventStatsNumAtRisk": 16
                },
                {
                    "OtherEventStatsGroupId": "EG001",
                    "OtherEventStatsNumAffected": 0,
                    "OtherEventStatsNumAtRisk": 16
                },
                {
                    "OtherEventStatsGroupId": "EG002",
                    "OtherEventStatsNumEvents": 2,
                    "OtherEventStatsNumAffected": 2,
                    "OtherEventStatsNumAtRisk": 16
                },
                {
                    "OtherEventStatsGroupId": "EG003",
                    "OtherEventStatsNumEvents": 5,
                    "OtherEventStatsNumAffected": 4,
                    "OtherEventStatsNumAtRisk": 16
                }
            ]
        }
    ],
    "protocolSection.referencesModule.seeAlsoLinks": [
        {
            "SeeAlsoLinkLabel": "NIH Clinical Center Detailed Web Page",
            "SeeAlsoLinkURL": "https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_000460-I.html"
        }
    ],
    "resultsSection.adverseEventsModule.seriousEvents": [
        {
            "SeriousEventTerm": "Anaemia",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "MedDRA 14.1",
            "SeriousEventAssessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "resultsSection.adverseEventsModule.seriousEvents.stats": [
                {
                    "SeriousEventStatsGroupId": "EG000",
                    "SeriousEventStatsNumAffected": 2,
                    "SeriousEventStatsNumAtRisk": 228
                },
                {
                    "SeriousEventStatsGroupId": "EG001",
                    "SeriousEventStatsNumAffected": 0,
                    "SeriousEventStatsNumAtRisk": 226
                }
            ]
        }
    ],
    "SecondaryIdInfos": [
        {
            "SecondaryId": "CTCRI 019826",
            "SecondaryIdType": "OTHER_GRANT",
            "SecondaryIdDomain": "Canadian Tobacco Control Research Initiative"
        }
    ],
    "documentSection.largeDocumentModule.largeDocs": [
        {
            "LargeDocTypeAbbrev": "Prot_SAP",
            "LargeDocHasProtocol": true,
            "LargeDocHasSAP": true,
            "LargeDocHasICF": false,
            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
            "LargeDocDate": "2022-10-19",
            "LargeDocUploadDate": "2023-06-07T12:03",
            "LargeDocFilename": "Prot_SAP_000.pdf",
            "LargeDocSize": 449133
        }
    ],
    "annotationSection.annotationModule.unpostedAnnotation.unpostedEvents": [
        {
            "UnpostedEventType": "RELEASE",
            "UnpostedEventDate": "2022-12-07"
        }
    ],
    "derivedSection.miscInfoModule.submissionTracking.submissionInfos": [
        {
            "SubmissionReleaseDate": "2022-12-07",
            "SubmissionResetDate": "2023-10-10"
        }
    ],
    "protocolSection.referencesModule.availIpds": [
        {
            "AvailIPDId": "AVD105248",
            "AvailIPDType": "Dataset Specification",
            "AvailIPDURL": "https://www.clinicalstudydatarequest.com",
            "AvailIPDComment": "For additional information about this study please refer to the GSK Clinical Study Register"
        }
    ]
}